Novo Nordisk A/S, the Danish health care company with U.S. headquarters in Plainsboro, has completed its $1.35 billion acquisition of Roseland-based drug delivery company Emisphere Technologies, Emisphere announced this week.
Novo Nordisk also acquired the related royalty stream obligations owed to affiliates of MHR Fund Management LLC for $450 million, bringing its total price to $1.8 billion.
“We are very pleased to reach today’s milestone and know Novo Nordisk will guide Emisphere into a promising new era,” Chairman Timothy Rothwell said in a prepared statement. “The Emisphere board of directors and its Special Committee are confident that this transaction has delivered substantial value to our stockholders.”
The deal was first announced in early November. Emisphere, which is known for its proprietary Eligen drug delivery technology, will now be a wholly owned subsidiary of Novo Nordisk.
